KOSPIBiotech & Pharma003060

Aprogen Biologics

₩1,178▼ 1.42%2026-11-18 close
Market Cap
₩35.4B
Turnover
₩91,098,283
Volume
80K
Shares out.
30.1M
PER
—
PBR
0.1×
EPS
-₩4,949
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Recovering, Losses Narrowing; Cash Flow and Balance Sheet in Focus

Revenue rose in each of the three quarters from the first quarter to the third quarter of 2026 and the operating loss narrowed year on year, but operating cash outflows, cumulative net losses and higher leverage remain the key variables.

  1. 1

    Revenue rose in each quarter from the first quarter to the third quarter of 2026, and third-quarter revenue of KRW 23.2 billion was up 9.8% year on year.

  2. 2

    The third-quarter 2026 operating loss narrowed to KRW 7.53 billion from KRW 10.7 billion a year earlier, while the net loss attributable to controlling shareholders widened to KRW 19.7 billion.

  3. 3

    Operating cash flow moved from an inflow of KRW 25.7 billion in 2022 to outflows of KRW 33.7 billion in 2023, KRW 31 billion in 2024 and KRW 38.2 billion in 2025.

  4. 4

    The debt-to-equity ratio rose from 34.6% in 2022 to 111.5% in 2025, with total liabilities of KRW 309.4 billion and total equity of KRW 277.6 billion at the end of 2025.

  5. 5

    Reports in early July 2026 said a KRW 50.8 billion convertible bond issuance was planned, with convertible shares equal to 1.5 times the existing shares outstanding.

02

Business structure

Aprogen Biologics runs a generic pharmaceutical business alongside a biologics business that manufactures antibody drugs. The pharma unit produces generic medicines, while the biologics unit makes antibody drugs at its Osong plant using perfusion culture.

According to WiseReport's company monitor, the main product mix is semiconductor process parts 32.40%, pharmaceuticals 29.51%, gastrointestinal drugs 13.23%, cardiovascular drugs 11.54% and others 13.32%.

JobKorea's financial analysis, which uses a different grouping, shows synthetic drugs at 78%, vacuum valves and semiconductor equipment parts at 13% and biopharmaceuticals at 7%, so the weight of each segment depends on the classification used.

The company merged a biologics production technology holder in 2022 and took a semiconductor equipment parts maker in as a subsidiary. Pharmaceutical sales are mostly domestic, and in 2025 gastrointestinal and cardiovascular drugs each had domestic shares above 95%.

Biologics sales remain small: according to a May 2026 MediCopharma report based on electronic disclosures, first-quarter 2026 biologics segment revenue was about KRW 200 million, or 1.11% of consolidated revenue of KRW 21.6 billion.

The company presents the Osong plant as a facility with top-tier global antibody capacity and is building a CDMO sales organization. In CDMO, large contract manufacturers such as Samsung Biologics dominate, so a mid-sized production base depends on winning new customers.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩21.1B-₩10.7B−50.5%
2025Q4₩20.4B-₩16B−78.5%
2026Q1₩21.6B-₩13.6B−63.0%
2026Q2₩23.1B-₩17.5B−75.7%
2026Q3₩23.2B-₩7.5B−32.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩65.2B-₩5.4B₩7.8B−8.3%1.9%34.6%
2023₩87.4B-₩57.5B-₩118.3B−65.8%−32.1%59.9%
2024₩67.4B-₩52.8B-₩105B−78.4%−27.7%56.1%
2025₩73.2B-₩60.4B-₩170.3B−82.4%−82.0%111.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On a reported basis, revenue went from KRW 65.2 billion in 2022 to KRW 87.4 billion in 2023, up 34.0% and the largest year in the 2022 to 2025 window, then fell 22.9% to KRW 67.4 billion in 2024 before rising 8.7% to KRW 73.2 billion in 2025.

The operating loss widened from KRW 5.43 billion in 2022 to KRW 57.5 billion in 2023, narrowed to KRW 52.8 billion in 2024 and widened again to KRW 60.4 billion in 2025, and the company has reported losses in each of the four years from 2022 to 2025. The operating margin fell from -8.3% in 2022 to -82.4% in 2025.

For 2025, the company attributed higher revenue mainly to the addition of a subsidiary and cited higher cost of sales as a driver of the wider operating loss, according to a February 2026 disclosure report.

Net income attributable to controlling shareholders swung from KRW 7.84 billion in 2022 to a net loss of KRW 118.3 billion in 2023 and then net losses of KRW 105 billion in 2024 and KRW 170.3 billion in 2025, which is three consecutive loss years.

The company said larger losses on financial assets, including credit loss provisions and disposal losses, pushed the pre-tax loss deeper in 2025. Consolidated net loss including non-controlling interests was KRW 168.3 billion in 2025, a different figure from the attributable number.

Operating cash flow went from an inflow of KRW 25.7 billion in 2022 to outflows of KRW 33.7 billion in 2023, KRW 31 billion in 2024 and KRW 38.2 billion in 2025.

Quarterly revenue bottomed at KRW 20.4 billion in the fourth quarter of 2025 and reached KRW 23.2 billion in the third quarter of 2026, with the operating loss shrinking to KRW 7.53 billion from KRW 17.5 billion in the prior quarter.

Net loss attributable to controlling shareholders, however, widened to KRW 19.7 billion in the third quarter of 2026 from KRW 14 billion in the second quarter, and the four quarters from the fourth quarter of 2025 to the third quarter of 2026 total a net loss of KRW 73.7 billion.

05

Industry analysis

Aprogen Biologics is a small-to-mid-sized company combining a pharmaceutical revenue base with biologics production capacity, and the two businesses differ clearly in character.

The pharma unit is a generic business centered on domestic prescription markets, so its demand structure differs from that of biotech peers, and its revenue depends on product sales and customer expansion. The biologics unit depends on contract development and manufacturing (CDMO) demand for antibody drugs.

Global CDMO orders tend to concentrate on large players with proven capacity and quality records, so compared with large CDMOs such as Samsung Biologics, this company is a mid-sized production base still in the stage of winning customers.

In biosimilars, Celltrion is a leading domestic company with extensive commercialization experience, while Aprogen's pipeline, including its Remicade biosimilar, is at the approval and clinical stages.

Alteogen focuses on subcutaneous formulation technology and SK bioscience on vaccines, so direct comparisons are limited.

The company's earnings base is still its pharmaceutical business, with biologics revenue around 1% of the total, so the timing at which biologics contracts begin to change the earnings mix is the central question. Approval timelines for biologics and demand for contract manufacturing remain industry-wide variables.

06

Outlook

Progress by business is as follows. As of the 2025 annual report, the Remicade biosimilar had obtained marketing approval in Japan and Latin America and completed Phase 3 trials. Rituxan is being prepared for a Phase 1 trial, and Herceptin is preparing for European marketing authorization after completing Phase 1.

For the Osong CDMO business, a late-2024 report said the plant was receiving audits from several domestic and overseas customers, including a European pharmaceutical company.

In the same report, the company said design of its fifth and sixth production lines had been completed and that it was pursuing a plan to expand plant scale by 1.5 times.

The report also said the plant was expected to handle finished-dosage manufacturing for a Parkinson's disease clinical drug from Aprogen's recently acquired affiliate, formerly known as Jiorit Energy.

However, MediCopharma reported in May 2026 that first-quarter 2026 biologics segment revenue was only about KRW 200 million, which some read as a sign that the conversion of plant capacity into commercial production is slow.

On financing, reports in early July 2026 said a KRW 50.8 billion convertible bond issuance was planned, with the stated purpose given as debt repayment. Collateral including the Osong bio plant was reported to have been provided against KRW 45 billion of borrowings from the largest shareholder.

Next checkpoints are whether CDMO contracts are signed, the utilization rate at the Osong plant, progress in biosimilar commercialization, and whether convertible bond proceeds are matched by operating cash flow.

07

Valuation

PER
—
PBR
0.1×
ROE
-33.3%
EPS
-₩4,949
BPS
₩13,622
Dividend per share
₩0

The price-to-earnings ratio cannot be calculated because the company has posted net losses attributable to controlling shareholders over the most recent four quarters, so there is no earnings-based multiple to compare.

The price-to-book ratio sits well below 1x, meaning the share price is far below book value per share. Equity fell from KRW 378.7 billion at the end of 2024 to KRW 277.6 billion at the end of 2025, so the lower multiple also reflects a smaller equity base.

No dividend is paid, and the dividend yield is below the industry average. Net income attributable to controlling shareholders was positive in 2022 at KRW 7.84 billion, but net losses have continued since 2023, which limits earnings-based comparisons.

Whether a low multiple signals value depends on whether asset backing or cash generation is the yardstick. The size of the convertible bond, which exceeds the market capitalization, adds a variable to per-share analysis because of potential share issuance.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Consecutive quarterly revenue growth

Revenue rose for three consecutive quarters, to KRW 21.6 billion, KRW 23.1 billion and KRW 23.2 billion in the first through third quarters of 2026. Third-quarter revenue was up 9.8% year on year. The recovery started from a trough of KRW 20.4 billion in the fourth quarter of 2025.

Narrower operating loss

The third-quarter 2026 operating loss of KRW 7.53 billion was smaller than KRW 10.7 billion a year earlier and smaller than KRW 17.5 billion in the second quarter. Whether this reflects lower costs or better gross profit will be visible in the next periodic report.

Progress on the Remicade biosimilar

The Remicade biosimilar has obtained approval in Japan and Latin America and completed Phase 3 trials. Herceptin is preparing for European marketing authorization after finishing Phase 1. If approvals convert into sales, the biologics share of revenue could rise, but no commercial launch timing has been specified.

09

Bear factors

Continued negative operating cash flow

Operating cash flow stayed negative at KRW 33.7 billion in 2023, KRW 31 billion in 2024 and KRW 38.2 billion in 2025. Revenue growth has not translated into cash generation. Press reports pointed to borrowing and convertible bonds as the means of covering liquidity needs.

Rising financial leverage

The debt-to-equity ratio rose from 34.6% in 2022 to 111.5% in 2025. Total liabilities were KRW 309.4 billion at the end of 2025, and total equity was KRW 277.6 billion, of which KRW 207.8 billion was attributable to controlling shareholders. Cumulative losses have reduced the equity base.

Convertible bonds and collateral

A KRW 50.8 billion convertible bond issuance was reported in early July 2026, with convertible shares equal to 1.5 times the shares outstanding, raising concerns about potential overhang.

Reports also said collateral of about KRW 63 billion, including Osong plant land, buildings and machinery, was provided against KRW 45 billion of borrowings from the largest shareholder.

10

Risk factors

Liquidity and funding

With operating cash outflows continuing, the company relies on borrowing and convertible bonds for funding. The large number of convertible shares has raised overhang concerns. The four-quarter attributable net loss total of KRW 73.7 billion is reducing equity.

Delays in biologics commercialization

Biologics production services revenue was only about KRW 200 million in the first quarter of 2026. A MediCopharma report said 2025 biologics segment revenue was KRW 5.6 billion against a projection of KRW 65.8 billion. Delays in biosimilar and contract manufacturing timelines are cited as the cause.

Governance and intragroup funding

Asset collateral for borrowings from the largest shareholder and a convertible bond placed with an affiliate mean the company's financial burden depends on intragroup funding flows. Changes in terms of transactions with affiliates are a key variable.

11

What to watch next

  1. Late January to mid-February 2027

    Typical timing for the fourth-quarter and full-year 2026 preliminary results. It is the first point at which 2026 operating loss and operating cash flow can be compared with 2025 values of KRW 60.4 billion and KRW -38.2 billion.

  2. Late March 2027

    Deadline for the 2026 annual report, generally 90 days after fiscal year-end. Annual revenue, debt-to-equity ratio and net loss attributable to controlling shareholders will be confirmed in this filing.

  3. Mid-May 2027

    Deadline for the first-quarter 2027 report, generally 45 days after quarter-end. It is the point to check progress on convertible bond conversion, borrowing repayment and biologics production services revenue.

  4. First half of 2027 (timing not fixed)

    Disclosure of CDMO contract signings and any change in Osong plant utilization. If contracts are disclosed, the next step is to check whether the biologics share of revenue changes.

12

Overall view

Aprogen Biologics posted operating losses from 2022 through 2025, while 2025 revenue rose to KRW 73.2 billion. Quarterly revenue rose for three straight quarters through the third quarter of 2026, and the operating loss narrowed to KRW 7.53 billion from KRW 10.7 billion a year earlier.

The net loss attributable to controlling shareholders widened to KRW 19.7 billion in the third quarter, and the four-quarter total is KRW 73.7 billion. On the balance sheet, the debt-to-equity ratio was 111.5% at the end of 2025, and operating cash outflows have continued since 2023.

Bullish factors include the revenue recovery, the narrower operating loss and approval and clinical progress on the Remicade biosimilar. Bearish factors include the absence of cash generation, the KRW 50.8 billion convertible bond and overhang concerns, and delayed commercialization of biologics production services.

The two sides remain in tension. The next checkpoints are operating cash flow and leverage in the 2026 annual report, and convertible bond progress and CDMO revenue in the first quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 12 more articles and sources
  1. comp.wisereport.co.kr
  2. jobkorea.co.kr
  3. comp.fnguide.com
  4. comp.wisereport.co.kr
  5. thevc.kr
  6. medicopharma.co.kr
  7. news.nate.com
  8. v.daum.net
  9. biotimes.co.kr
  10. markets.hankyung.com
  11. kr.investing.com
  12. google.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis